search

Active clinical trials for "Macular Degeneration"

Results 291-300 of 1337

Functionally Validated Structural Endpoints for Early AMD

Age-related Macular DegenerationAging

Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD). This research plan is designed to elucidate the structural (anatomical) basis of this visual deficit using cellular- and subcellular level imaging of the retina and its supporting tissues in living people. An accurate map and timeline of structure-function relationships in persons tested for night vision will result in functionally validated structural endpoints for early AMD trials, as well as define major biologic effects for development into future treatments.

Active49 enrollment criteria

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and...

Wet Age-related Macular DegenerationRetinal Vein Occlusion1 more

This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg

Terminated40 enrollment criteria

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered...

Dry Age-related Macular DegenerationMacular Degeneration5 more

This is an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to AMD

Terminated25 enrollment criteria

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration...

Dry Age-related Macular DegenerationGeographic Atrophy3 more

This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Terminated26 enrollment criteria

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy...

Geographic Atrophy

This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.

Terminated6 enrollment criteria

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy)...

Age-Related Macular Degeneration

To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.

Terminated6 enrollment criteria

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

Macular Degeneration

The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.

Terminated53 enrollment criteria

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary...

Geographic AtrophyMacular Degeneration

This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.

Terminated4 enrollment criteria

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients...

Age-Related Macular DegenerationChoroidal Neovascularization

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

Terminated4 enrollment criteria

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal...

Macular DegenerationChoroidal Neovascularization

This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration

Terminated5 enrollment criteria
1...293031...134

Need Help? Contact our team!


We'll reach out to this number within 24 hrs